Literature DB >> 12392593

Perception of the risk of adverse drug reactions: differences between health professionals and non health professionals.

V Bongard1, S Ménard-Taché, H Bagheri, K Kabiri, M Lapeyre-Mestre, J L Montastruc.   

Abstract

AIMS: To investigate how risk of adverse drug reactions (ADRs) of several drug classes is perceived by health vs non health professionals.
METHODS: Four hundred health professionals (i.e. 278 general practitioners, 76 pharmacists and 46 pharmacovigilance professionals) and 153 non health professionals were interviewed. Visual analogue scales were used to define a score of perceived risk of ADRs associated with each drug class (ranking from 0 to 10).
RESULTS: Anticoagulants were ranked as the most dangerous drugs by general practitioners [median score (25th-75th centiles): 7.9 (6.7-9.0)], pharmacists [8.7 (7.8-9.7)] and pharmacovigilance professionals [8.1 (7.2-9.0)]. For non health professionals, the class ranked first was sleeping pills [8.7 (7.2-9.4)] followed by tranquillisers [8.2 (6.4-9.2)] and antidepressants [8.0 (5.9-9.1)]. Aspirin was listed in the last position by non health professionals [3.4 (1.5-5.4)].
CONCLUSIONS: There are major differences in the perception of risk of ADRs between health professionals and non health professionals.

Entities:  

Mesh:

Year:  2002        PMID: 12392593      PMCID: PMC1874441          DOI: 10.1046/j.1365-2125.2002.01674.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres.

Authors:  P Pouyanne; F Haramburu; J L Imbs; B Bégaud
Journal:  BMJ       Date:  2000-04-15

2.  A survey on factors that could affect adverse drug reaction reporting according to hospital pharmacists in Great Britain.

Authors:  D Sweis; I C Wong
Journal:  Drug Saf       Date:  2000-08       Impact factor: 5.606

Review 3.  Epidemiology of NSAID induced gastrointestinal complications.

Authors:  G Singh; G Triadafilopoulos
Journal:  J Rheumatol Suppl       Date:  1999-04

4.  Hospital-based survey of doctors' attitudes to adverse drug reactions and perception of drug-related risk for adverse reaction occurrence.

Authors:  M Cosentino; O Leoni; C Oria; D Michielotto; E Massimo; S Lecchini; G Frigo
Journal:  Pharmacoepidemiol Drug Saf       Date:  1999-04       Impact factor: 2.890

5.  Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system.

Authors:  A Alvarez-Requejo; A Carvajal; B Bégaud; Y Moride; T Vega; L H Arias
Journal:  Eur J Clin Pharmacol       Date:  1998-08       Impact factor: 2.953

6.  Attitudes to adverse drug reaction reporting by medical practitioners in a Northern Italian district.

Authors:  M Cosentino; O Leoni; F Banfi; S Lecchini; G Frigo
Journal:  Pharmacol Res       Date:  1997-02       Impact factor: 7.658

7.  Under-reporting of adverse drug reactions in general practice.

Authors:  Y Moride; F Haramburu; A A Requejo; B Bégaud
Journal:  Br J Clin Pharmacol       Date:  1997-02       Impact factor: 4.335

Review 8.  The epidemiology of nonsteroidal anti-inflammatory drugs.

Authors:  J Tenenbaum
Journal:  Can J Gastroenterol       Date:  1999-03       Impact factor: 3.522

Review 9.  Drug-related hospital admissions.

Authors:  T R Einarson
Journal:  Ann Pharmacother       Date:  1993 Jul-Aug       Impact factor: 3.154

Review 10.  Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology.

Authors:  D McCarthy
Journal:  Am J Med       Date:  1998-11-02       Impact factor: 4.965

View more
  17 in total

1.  Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies.

Authors:  Priya Bahri
Journal:  Drug Saf       Date:  2010-12-01       Impact factor: 5.606

2.  Risk perception in drug therapy.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

3.  Perception of risk of adverse drug reactions by medical students: influence of a 1 year pharmacological course.

Authors:  G Durrieu; C Hurault; V Bongard; C Damase-Michel; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  2007-03-22       Impact factor: 4.335

4.  Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006.

Authors:  Lise Aagaard; Lars Hougaard Nielsen; Ebba Holme Hansen
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

5.  Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice: a study in a French emergency department.

Authors:  Pascale Olivier; Olivier Boulbés; Marie Tubery; Dominique Lauque; Jean-Louis Montastruc; Maryse Lapeyre-Mestre
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance.

Authors:  L Aagaard; C E Hallgreen; E H Hansen
Journal:  Int J Obes (Lond)       Date:  2016-08-01       Impact factor: 5.095

7.  Knowledge and perceptions of the risks of non-steroidal anti-inflammatory drugs among orthopaedic patients in Thailand.

Authors:  Pacharaporn Phueanpinit; Juraporn Pongwecharak; Janet Krska; Narumol Jarernsiripornkul
Journal:  Int J Clin Pharm       Date:  2016-07-29

Review 8.  Active pharmacovigilance in China: recent development and future perspectives.

Authors:  Xinling Li; Haona Li; Jianxiong Deng; Feng Zhu; Ying Liu; Wenge Chen; Zhihua Yue; Xuequn Ren; Jielai Xia
Journal:  Eur J Clin Pharmacol       Date:  2018-04-10       Impact factor: 2.953

9.  Patients' knowledge of adverse reactions to current medications.

Authors:  Garret Cullen; Emer Kelly; Frank E Murray
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

10.  Perception of the risk of gastrointestinal adverse drug reactions with non-steroidal anti-inflammatory drugs (including coxibs): differences among general practitioners, gastroenterologists and rheumatologists.

Authors:  J L Montastuc; V Bongard; M Lapeyre-Mestre
Journal:  Eur J Clin Pharmacol       Date:  2003-10-11       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.